You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives USFDA final approval for Valsartan and Hydrochlorothiazide Tablets

Capital Market 

has received the final approval from the USFDA to market and Tablets USP (US RLD Diovan HCT Tablets) in the strengths of 80 mg/12.5 mg, 160 mtg/12.5 mg, 160 mg/25 mg, 320 mtg/12.5 mg, and 320 mg/25 mg.

The drug is used to treat Lowering helps prevent strokes, and kidney problems. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sat, March 16 2019. 13:23 IST